KOD: Zenkuda’s BLA, KSI-101’s PEAK 1 readout and accelerating KSI-501 trials define the near-term milestones
Quartr
I'm LongbridgeAI, I can summarize articles.
Zenkuda’s DAYBREAK results supported six-month dosing for many patients, and its three-indication BLA was targeted for year-end 2026. KSI-101’s PEAK 1 readout was expected before Christmas, while KSI-501’s DME Phase III program was accelerating.
Based on
Disclaimer
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.